TLDR:
- Pasithea Stock Soars 56% on $60M Offering and Strong Institutional Backing
- KTTAW Stock Jumps 56% as Pasithea Raises $60 Million to Fuel Growth
- Pasithea’s Stock Gains 56% After $60 Million Offering and Pipeline Boost
- Pasithea Therapeutics Stock Soars After Announcing $60 Million Offering
- KTTAW Stock Surges 56% as Pasithea Secures $60 Million for Drug Development
Pasithea Therapeutics Corp. (Nasdaq: KTTAW) saw its stock surge by 56.86%, reaching $0.0549 as of 11:09 AM EST following the announcement of its public offering.
Pasithea Therapeutics Corp., KTTAW
The company priced the offering at $0.75 per share, expecting to raise $60 million in gross proceeds. The surge in stock price reflects positive market sentiment, likely driven by the funding boost and institutional backing.
$60 Million Offering and Institutional Support
Pasithea priced an offering of 80,000,000 shares at $0.75 per share, bringing in gross proceeds of $60 million. The company plans to use the funds for general corporate purposes, including research, clinical trials, and potential acquisitions. The offering is scheduled to close on December 1, 2025, and is expected to extend Pasithea’s cash runway through at least the first half of 2028.
The offering was led by prominent healthcare investors, such as Vivo Capital and Janus Henderson Investors, signaling strong demand for the company’s stock. This financial support enhances Pasithea’s ability to continue the development of PAS-004, its lead drug candidate, which is currently in clinical trials for the treatment of neurofibromatosis. The backing from such reputable investors also suggests confidence in Pasithea’s long-term potential in the biotech sector.
The issuance of 80 million shares will dilute existing shareholders, which could affect stock performance in the short term. The proceeds from the offering will help fund ongoing research and clinical activities, supporting Pasithea’s growth initiatives. Still, investors should monitor the use of funds and the company’s ability to meet its development milestones in the coming years.
Strengthening Cash Position and Future Growth Prospects
The $60 million offering will strengthen Pasithea’s cash position, ensuring the company can continue developing its pipeline. Pasithea is currently advancing PAS-004, a next-generation MEK inhibitor, through clinical trials for the treatment of RASopathies and other serious diseases. With this funding, Pasithea can accelerate the research and development of PAS-004, as well as expand its efforts in preclinical studies and clinical trials.
Pasithea has emphasized the strategic importance of these funds in supporting its ongoing activities and expanding its pipeline. The company has already demonstrated strong progress in its clinical trials and now has the financial backing to build on that momentum. The $60 million will help ensure that the company meets its upcoming research and development goals and continues to grow in the competitive biotech landscape.
With a cash runway extended into 2028, Pasithea is well-positioned to make significant progress on its drug development. The company’s ability to secure such significant funding from institutional investors reflects confidence in its strategies and prospects. As the company continues to develop PAS-004 and other treatments, it aims to deliver long-term value to shareholders.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
